The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Subscribe To Our Newsletter & Stay Updated
